This post by MDV brings to my mind two mind boggli
Post# of 148246
(Total Views: 593)
Posted On: 01/11/2021 7:29:31 PM
Re: MD VIROLOGIST #72214
This post by MDV brings to my mind two mind boggling CD12 scenarios.
First, MDV offers the possibility that mortality is leronlimab dose-respondent.
Second, it occurs to me that RO could prove dose dependent life saving capability of LL, but Cytodyn doesn't have the data either because it was not done on all CD12 patients or because what RO data was collected is not in Cytodyn's possesion and is thus not presentable to the FDA.
"What I can say is in the first 100 patients there was quite a difference in RO between the two cohorts, survival data of course is forthcoming. Occupancy can vary amongst treated patient, but if those with the highest occupancy survive it could lead to fast track."
The first mind-boggling concept that MDV offers is the following:
What if the only CD12 patients who died were patients who had some "low" level of RO.
Maybe every patient who survived has RO greater than 90% at day seven, for example.
That is a p-value of of at least as good as .001.
This situation seems potentially possible to me as the dose of leronlimab was just grabbed from HIV.
Somewhat hilariously, the only way to set the dose for covid was to use the Patterson CCR5 RO data that was just rejected by the FDA for HIV!?!?!?!?!?!?
There have never been any dose limiting LL toxicities observed in humans.
Maybe covid just needs a higher dose than HIV.
We already have a very strong hypothesis that the dose method for covid is wrong and should be intravenous instead of subcutaneous.
Covid is an emergency condition. HIV is chronic.
Maybe the covid dose was not high enough and that's why the covid LL patients died. CD12 RO tests could indicate that if some LL CD12 patients had been given a higher LL dose, then all of the covid LL patients would have survived.
Well, even if that possibility doesn't make your head spin, then the second possibility could still make your head explode.
What if Cytodyn does not have the RO data that demonstrates that LL covid survival is dose dependent?
What if the reason is because CD12 RO was not done because of the split with Patterson?
What if some data is done, but Cytodyn doesn't have it because of their spat with Patterson?
First, MDV offers the possibility that mortality is leronlimab dose-respondent.
Second, it occurs to me that RO could prove dose dependent life saving capability of LL, but Cytodyn doesn't have the data either because it was not done on all CD12 patients or because what RO data was collected is not in Cytodyn's possesion and is thus not presentable to the FDA.
"What I can say is in the first 100 patients there was quite a difference in RO between the two cohorts, survival data of course is forthcoming. Occupancy can vary amongst treated patient, but if those with the highest occupancy survive it could lead to fast track."
The first mind-boggling concept that MDV offers is the following:
What if the only CD12 patients who died were patients who had some "low" level of RO.
Maybe every patient who survived has RO greater than 90% at day seven, for example.
That is a p-value of of at least as good as .001.
This situation seems potentially possible to me as the dose of leronlimab was just grabbed from HIV.
Somewhat hilariously, the only way to set the dose for covid was to use the Patterson CCR5 RO data that was just rejected by the FDA for HIV!?!?!?!?!?!?
There have never been any dose limiting LL toxicities observed in humans.
Maybe covid just needs a higher dose than HIV.
We already have a very strong hypothesis that the dose method for covid is wrong and should be intravenous instead of subcutaneous.
Covid is an emergency condition. HIV is chronic.
Maybe the covid dose was not high enough and that's why the covid LL patients died. CD12 RO tests could indicate that if some LL CD12 patients had been given a higher LL dose, then all of the covid LL patients would have survived.
Well, even if that possibility doesn't make your head spin, then the second possibility could still make your head explode.
What if Cytodyn does not have the RO data that demonstrates that LL covid survival is dose dependent?
What if the reason is because CD12 RO was not done because of the split with Patterson?
What if some data is done, but Cytodyn doesn't have it because of their spat with Patterson?
(3)
(1)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼